Data from A Phase I Dose Escalation and Expansion Study of the Anticancer Stem Cell Agent Demcizumab (Anti-DLL4) in Patients with Previously Treated Solid Tumors

Autor: Branimir Sikic, Jakob Dupont, Lu Xu, Ann M. Kapoun, Robert J. Stagg, Matthew A. Gubens, Rashmi Chugh, Georgy Manikhas, Peter D. Eisenberg, David C. Smith

Purpose: This phase I trial evaluated the safety, pharmacokinetics, and pharmacodynamics of demcizumab (OMP-21M18), a humanized IgG2 mAb targeting the Notch ligand DLL4 in adult patients with advanced malignancies.Experimental Design: Standard 3+3 de

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cde00993c39a6fb0037d43905375297
https://doi.org/10.1158/1078-0432.c.6523656

Adjuvant vemurafenib in resected, BRAF V600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

Autor: Michele Maio, Karl Lewis, Lev Demidov, Mario Mandalà, Igor Bondarenko, Paolo A Ascierto, Christopher Herbert, Andrzej Mackiewicz, Piotr Rutkowski, Alexander Guminski, Grant R Goodman, Brian Simmons, Chenglin Ye, Yibing Yan, Dirk Schadendorf, Gabriela Cinat, Luis Enrique Fein, Michael Brown, Andrew Haydon, Adnan Khattak, Catriona McNeil, Phillip Parente, Jeremy Power, Rachel Roberts-Thomson, Shahneen Sandhu, Craig Underhill, Suresh Varma, Thomas Berger, Ahmad Awada, Nathalie Blockx, Veronique Buyse, Jeroen Mebis, Fábio André Franke, Sérgio Jobim de Azevedo, Nicolas Silva Lazaretti, Rahima Jamal, Catalin Mihalcioiu, Teresa Petrella, Kerry Savage, Xinni Song, Ralph Wong, Nina Dabelic, Stjepko Plestina, Zeljko Vojnovic, Petr Arenberger, Ivo Kocak, Ivana Krajsova, Eugen Kubala, Bohuslav Melichar, Yvetta Vantuchova, Kadri Putnik, Brigitte Dreno, Caroline Dutriaux, Jean-Jacques Grob, Pascal Joly, Jean-Philippe Lacour, Nicolas Meyer, Laurent Mortier, Luc Thomas, Michael Fluck, Thilo Gambichler, Jessica Hassel, Axel Hauschild, Paul Donnellan, John McCaffrey, Derek Power, Samuel Ariad, Gil Bar-Sela, Daniel Hendler, Ilan Ron, Jacob Schachter, Paolo Ascierto, Alfredo Berruti, Luca Bianchi, Vanna Chiarion Sileni, Francesco Cognetti, Riccardo Danielli, Anna Maria Di Giacomo, Luca Gianni, Aron Goldhirsch, Michele Guida, Paolo Marchetti, Paola Queirolo, Armando Santoro, Ellen Kapiteijn, Paula Ferreira, Georgy Gafton, Yulia Makarova, Zoran Andric, Nada Babovic, Darjana Jovanovic, Lidija Kandolf Sekulovic, Graham Cohen, Lydia Dreosti, Daniel Vorobiof, Maria Teresa Curiel Garcia, Roberto Diaz Beveridge, Margarita Majem Tarruella, Ivan Marquez Rodas, Jose-M Puliats Rodriguez, Antonio Rueda Dominguez, Marianne Maroti, Karin Papworth, Olivier Michielin, Ewan Brown, Pippa Corrie, Mark Harries, Satish Kumar, Agustin Martin-Clavijo, Mark Middleton, Poulam Patel, Toby Talbot, Sanjiv Agarwala, Paul Chapman, Robert Conry, Gary Doolittle, Tara Gangadhar, Sigrun Hallmeyer, Omid Hamid, Leonel Hernandez-Aya, Douglas Johnson, Frederic Kass, Tatjana Kolevska, Scott Lunin, April Salama, Branimir Sikic, Bradley Somer, David Spigel, Eric Whitman

Summary Background Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC–III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAF V600 muta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ca377ad3c682462789b57095f06c16
http://hdl.handle.net/11379/501841

A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer.

Autor: Kim N. Chi, Stephen K. Chia, Ross Dixon, Michael J. Newman, Vince J. Wacher, Branimir Sikic, Karen A. Gelmon

Publikováno v: Investigational New Drugs; Aug2005, Vol. 23 Issue 4, p311-315, 5p